Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tectonic Therapeutic (TECX) Research & Development (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Research & Development data on record, last reported at $20.9 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 60.1% to $20.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $71.3 million, a 63.65% increase, with the full-year FY2025 number at $63.5 million, up 53.49% from a year prior.
  • Research & Development reached $20.9 million in Q1 2026 per TECX's latest filing, up from $16.3 million in the prior quarter.
  • Over the last five years, Research & Development for TECX hit a ceiling of $20.9 million in Q1 2026 and a floor of $7.1 million in Q2 2024.
  • A 5-year average of $14.1 million and a median of $15.9 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 60.35% in 2023, then soared 142.93% in 2025.
  • Tracing TECX's Research & Development over 5 years: stood at $18.1 million in 2022, then crashed by 60.35% to $7.2 million in 2023, then rose by 27.31% to $9.2 million in 2024, then skyrocketed by 78.47% to $16.3 million in 2025, then grew by 27.72% to $20.9 million in 2026.
  • Business Quant data shows Research & Development for TECX at $20.9 million in Q1 2026, $16.3 million in Q4 2025, and $16.9 million in Q3 2025.